Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice

Cancer Research

Volumn 57, Issue 4, 1997, Pages 559-563

  Jankun, Jerzy ^a   Keck, Rick W ^a   Skrzypczak Jankun, Ewa ^b   Swiercz, Rafal ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZAMIDINE; AMILORIDE; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; DRUG EFFECT; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR REGRESSION; TUMOR VOLUME;

AMILORIDE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BENZAMIDINES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; PENICILLINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031056819     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Conese, M., and Blasi, F. The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin. Haematol., 8: 365-389, 1995.
2. Ossowski, L. In vitro invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107: 2437-2445, 1988.
3. Jankun, J., Merrick, W. H., and Goldblatt, P. J. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell. Biochem., 53: 135-144, 1993.
4. Jankun, J., Maher, V. M., and McCormick, J. J. Malignant transformation of human fibroblasts correlates with increased activity of receptor bound plasminogen activator. Cancer Res., 51: 1221-1226, 1991.
5. Festuccia, C., Vincentini, C., di Pasquale, A. B., Aceto, G., Zazzeroni, F., Miano, L., and Bologna, M. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol. Res., 7: 131-138, 1993.
6. Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L. G., Brodt., P., Goltzman, D., and Rabbani, S. A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54: 2372-2377, 1994.
7. Wilson, M. J., and Sinha, A. A. Plasminogen activator and metalloproteinase activities of DU-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasion behavior. Cell. Mol. Biol. Res., 59: 751-760, 1993.
8. Billstrom, A., Hartley-Asp, B., Lancander, I., Batra, S., and Astedt, B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int. J. Cancer, 61: 542-547, 1995.
9. Sparks, R. L., Pool, T. B., Smith N. K., and Cameron, I. L. Effects of amiloride on growth and intracellular element content of tumor cells in vivo. Cancer Res., 43: 73-77, 1983.
10. Iishi, H., Tatsuta, M., Baba, M., Yano, H., Uehara, H., and Nakaizumi, A. Suppression by amiloride of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane. Int. J. Cancer, 63: 716-719, 1995.
11. Koo, J. Y., Parekh, D., Townsend, C. M., Jr., Saydjari, R., Evers, B. M., Faire, A., Ishizuka, J., and Thompson, J. C. Amiloride inhibits the growth of human colon cancer cells in vitro. Surg. Oncol., 1: 385-389, 1992.
12. Pepper, M. S. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol., 122: 673-676, 1993.
13. Hasuda, K., Lee, C., and Tannock, I. F. Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl) amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH. Oncol. Res., 6: 259-268, 1994.
14. Berkenpas, M. B., Lawrence, D. A., and Ginsburg, D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J., 14: 2969-2977, 1995.
15. Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D., and Goldsmith, E. J. Structural basis of latency in plasminogen activator inhibitor-1. Nature (Lond.), 355: 270-273, 1992.
16. Lawrence, D. A., Strandberg, L., Grundstrom, T., and Ny, T. Purification of active human plasminogen activator inhibitor-1 from Escheriehia coli. Comparison with natural and recombinant forms purified from eukaryotic cells. Eur. J. Biochem., 186: 523-533, 1989.
17. Harvey, S. R., Lawrence, D. D., Madeja, J. M., Abbey, S. J., and Markus, G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin. Exp. Metastasis, 6: 431-450, 1988.
18. Hollas, W., Hoosein, N., Chung, L. W., Mazar, A., Henkin, J., Kariko, K., Barnathan, E. S., and Boyd, D. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemostasis, 68: 662-666, 1992.
19. Spargon, G., Phillips, C., Novak, U. K., Ponting, C. P., Sauders, D., Dobson, C. M., Stuart, D. I., and Jones, E. Y. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure, 3: 681-691, 1995.
20. InsightII, 95.0/3.0.0. User's Guide MSI, 1995.
21. Towle, M. J., Lee, A., Maduakor, E. C., Schwartz, C. E., Bridges, A. J., and Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo(b)thiophene-2-carboxyamidines: an important new class of selective synthetic urokinase inhibitors. Cancer Res., 53: 2533-2539, 1993.
22. Higazi, A. A., and Mayer, M. In vitro inhibition of urokinase by penicillin. Thromb. Haemostasis, 60: 305-307, 1988.
23. Branden, C., and Tooze, J. Introduction to Protein Structure, pp. 231-246. New York and London: Grand Publishing, Inc., 1991.
24. Tucker, H. M., Mottonen, J., Goldsmith, E. J., and Gerard, R. D. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency. Nat. Struc. Biol., 2: 442-445, 1995.